Cover Image

Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome

Hiroki Hosoi, Kazuo Hatanaka, Shogo Murata, Toshiki Mushino, Kodai Kuriyama, Akinori Nishikawa, Nobuyoshi Hanaoka, Shinobu Tamura, Hideki Nakakuma, Takashi Sonoki
  • Hiroki Hosoi
    Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
  • Kazuo Hatanaka
    Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
  • Shogo Murata
    Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
  • Toshiki Mushino
    Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
  • Kodai Kuriyama
    Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
  • Akinori Nishikawa
    Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
  • Nobuyoshi Hanaoka
    Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
  • Shinobu Tamura
    Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan
  • Hideki Nakakuma
    Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan

Abstract

Sezary syndrome (SS) is a leukemic form of cutaneous T-cell lymphoma and is chemo-resistant. Allogeneic hematopoietic stem cell transplantation is a promising therapy for SS; however, relapse is common. Therapeutic options after relapse have not been established. We managed an SS patient with hematological relapse within one month after transplantation. After discontinuation of immunosuppressants, she achieved complete remission and remained relapse-free. The chimeric analyses of Tcells showed that the full recipient type became complete donor chimera after immunological symptoms. This clinical course suggested that discontinuation of immunosuppressants may result in a graftversus- tumor effect, leading to the eradication of lymphoma cells.

Keywords

Sezary syndrome; Allo-HSCT; Graft versus tumor effect

Full Text:

PDF
Submitted: 2017-11-16 06:45:40
Published: 2018-09-05 09:22:38
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
35

Views:
PDF
3

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2018 Hiroki Hosoi, Kazuo Hatanaka, Shogo Murata, Toshiki Mushino, Kodai Kuriyama, Akinori Nishikawa, Nobuyoshi Hanaoka, Shinobu Tamura, Hideki Nakakuma, Takashi Sonoki

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy